according to J&J's pharma unit Janssen. Maintaining remission at 32 weeks was a key secondary endpoint, hit by 55% of the Spravato group and 37% of patients taking quetiapine, with the proportion ...

Pharmaceutical companies cannot patent generic ketamine for depression, but Janssen, a subsidiary of Johnson & Johnson, patented esketamine, which it named Spravato. The cost of the two drugs ...

which is marketed under the brand name Spravato, without having to be on another type of antidepressant, according to a statement from the drug's manufacturer, Janssen Pharmaceuticals, that was ...

NICE has rejected regular NHS funding for Janssen’s depression spray Spravato (esketamine) for a second time, although the company says it could salvage the situation by providing further data ...

SPRAVATO has been increasing in sales for the last several quarters, and I believe last year it was the fastest growing product in Janssen's portfolio. Did we hit a billion in sales last year?

Living Local 15 host Jessica Williams is joined by Sean Goddard, a Psychiatric Nurse Practitioner and Owner of Viking Psychiatry, to speak about the recent approval for Spravato as a monotherapy ...

Spravato (esketamine) has possible interactions with alcohol, some other drugs, and certain supplements. Examples include Adderall and benzodiazepines such as clonazepam (Klonopin). Talk with your ...

Johnson & Johnson has won Food and Drug Administration expanded approval of its Spravato nasal spray as a lone therapy for adults with treatment-resistant depression. J&J on Tuesday said the green ...

41,366 people played the daily Crossword recently. Can you solve it faster than others?41,366 people played the daily Crossword recently. Can you solve it faster than others?